EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Adherence to the GOLD Guidelines in Primary Care: Data from the Swiss COPD Cohort

Veronika Mangold, Maria Boesing iD, Camille Berset, Pierre-Olivier Bridevaux iD, Thomas Geiser, Ladina Joos Zellweger, Malcolm Kohler, Giorgia Lüthi-Corridori, Sabrina Maier, David Miedinger, Robert Thurnheer, Christophe von Garnier und 1 weitere

Journal of Clinical Medicine · 20.10.2023 · 12 (20) · 6636

DOI: 10.3390/jcm12206636 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.10.2023. Verfasst von Veronika Mangold und 12 weiteren Autor:innen. Beteiligte Einrichtung: University Center of Internal Medicine, Cantonal Hospital Baselland, 4410 Liestal, Switzerland. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim Switzerland, Pfizer Switzerland, Novartis Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Introduction

Chronic obstructive pulmonary disease (COPD) and its associated morbidity and mortality are a global burden on both affected patients and healthcare systems. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issues guidelines with the aim of improving COPD management. Previous studies reported significant variability in adherence to these recommendations. The objective of this study was to evaluate Swiss primary practitioners’ adherence to the GOLD guidelines for the pharmacological treatment of stable COPD. (2)

Methods

We studied patients who were included in the Swiss COPD cohort study, an ongoing prospective study in a primary care setting, between 2015 and 2022. The key inclusion criteria are age ≥ 40 years, FEV1/FVC ratio < 70%, and a smoking history of at least 20 pack-years. Adherence to the GOLD guidelines was assessed per visit and over time. (3)

Results

The data of 225 COPD patients (mean age 67 ± 9 years, 64% male) and their respective 1163 visits were analyzed. In 65% of visits (726/1121), treatment was prescribed according to the GOLD guidelines. Non-adherence was most common in GOLD groups A and B (64% and 33%) and mainly consisted of over-treatment (two long-acting bronchodilators in group A (98/195, 50%) and ICS in groups A (21/195, 11%) and B (198/808, 25%)). In group D, the prescriptions conformed with the guidelines in 99% of cases (109/108). Guideline adherence was associated with high symptom load (COPD Assessment Test) (OR 1.04, p = 0.002), high number of exacerbations (OR = 2.07, p < 0.001), asthma overlap (OR 3.36, p = 0.049), and diabetes mellitus (OR 2.82, p = 0.045). (4)

Conclusion

These results confirm a conflict between the GOLD recommendations and primary practice, mainly concerning over-treatment in GOLD groups A and B. Patients with high symptom load, high exacerbation risk, asthma overlap, and diabetes mellitus are more likely to be treated in conformity with the guidelines. Further research is needed to uncover the reasons for the discrepancies and to design strategies for improvement.

Schlagwörter

Stichwörter der Autor:innen

COPDGOLD guidelinesadherencebronchodilatorsinhaled corticosteroidsprimary care

Autor:innen und Institutionen

  • University Center of Internal Medicine, Cantonal Hospital Baselland, 4410 Liestal, Switzerland.
  • Faculty of Medicine, University of Basel, 4056 Basel, Switzerland.
  • Clinic of Pneumology, Hospital of Valais, University of Geneva, 1205 Geneva, Switzerland.
  • Department of Pulmonary Medicine and Allergology, University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Department of Pneumology, Claraspital, 4058 Basel, Switzerland.
  • Department of Pneumology, University Hospital Zürich, 8091 Zürich, Switzerland.

ORCID-Profile: Maria Boesing, Pierre-Olivier Bridevaux, Jörg Daniel Leuppi

Förderung

  • Boehringer Ingelheim Switzerland
  • Pfizer Switzerland
  • Novartis Switzerland
  • Astra Zeneca Switzerland
  • GlaxoSmithKline Switzerland
  • Boehringer Ingelheim GmbH Switzerland
  • Pfizer AG Switzerland
  • Novartis AG Switzerland

Zitieren

APA

Mangold, V., Boesing, M., Berset, C., Bridevaux, P. O., Geiser, T., Joos Zellweger, L., Kohler, M., Lüthi-Corridori, G., Maier, S., Miedinger, D., Thurnheer, R., von Garnier, C., & Leuppi, J. D. (2023). Adherence to the GOLD Guidelines in Primary Care: Data from the Swiss COPD Cohort. Journal of Clinical Medicine, 12(20), 6636. https://doi.org/10.3390/jcm12206636

Vancouver

Mangold V, Boesing M, Berset C, Bridevaux PO, Geiser T, Joos Zellweger L, et al. Adherence to the GOLD Guidelines in Primary Care: Data from the Swiss COPD Cohort. Journal of Clinical Medicine. 2023;12(20):6636. doi:10.3390/jcm12206636

BibTeX
@article{Mangold2023,
  author = {Mangold, Veronika and Boesing, Maria and Berset, Camille and Bridevaux, Pierre-Olivier and Geiser, Thomas and Joos Zellweger, Ladina and Kohler, Malcolm and Lüthi-Corridori, Giorgia and Maier, Sabrina and Miedinger, David and Thurnheer, Robert and von Garnier, Christophe and Leuppi, Jörg Daniel},
  title = {Adherence to the GOLD Guidelines in Primary Care: Data from the Swiss COPD Cohort},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {20},
  pages = {6636},
  doi = {10.3390/jcm12206636}
}
Kostenlos starten →